BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 29799325)

  • 1. The Relationship Between Guideline-Recommended Initiation of Therapy, Outcomes, and Cost for Patients with Metastatic Non-Small Cell Lung Cancer.
    Casebeer A; Antol DD; DeClue RW; Hopson S; Li Y; Khoury R; Michael T; Sehman M; Parikh A; Stemkowski S; Bunce M
    J Manag Care Spec Pharm; 2018 Jun; 24(6):554-564. PubMed ID: 29799325
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-World Costs of Adverse Events in First-Line Treatment of Metastatic Non-Small Cell Lung Cancer.
    Engel-Nitz NM; Johnson MP; Bunner SH; Ryan KJ
    J Manag Care Spec Pharm; 2020 Jun; 26(6):729-740. PubMed ID: 32463768
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-World Economic Outcomes During Time on Treatment Among Patients Who Initiated Sunitinib or Pazopanib as First Targeted Therapy for Advanced Renal Cell Carcinoma: A Retrospective Analysis of Medicare Claims Data.
    Vogelzang NJ; Pal SK; Ghate SR; Li N; Swallow E; Peeples M; Zichlin ML; Meiselbach MK; Perez JR; Agarwal N
    J Manag Care Spec Pharm; 2018 Jun; 24(6):525-533. PubMed ID: 29799328
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adherence, Persistence, and Health Care Costs for Patients Receiving Dipeptidyl Peptidase-4 Inhibitors.
    Rascati KL; Worley K; Meah Y; Everhart D
    J Manag Care Spec Pharm; 2017 Mar; 23(3):299-306. PubMed ID: 28230454
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of early vs delayed progression on clinical and economic outcomes in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors as first-line therapy: results from the IMPACT RCC claims data analysis.
    Hutson TE; Liu FX; Dieyi C; Kim R; Krulewicz S; Kasturi V; Bhanegaonkar A
    J Manag Care Spec Pharm; 2021 Sep; 27(9):1171-1181. PubMed ID: 34165322
    [No Abstract]   [Full Text] [Related]  

  • 6. Health care resource utilization and costs associated with advanced or metastatic nonsmall cell lung cancer in the United States.
    Zhang X; Beachler DC; Masters E; Liu F; Yang M; Dinh J; Jamal-Allial A; Kolitsopoulos F; Lamy FX
    J Manag Care Spec Pharm; 2022 Feb; 28(2):255-265. PubMed ID: 34854733
    [No Abstract]   [Full Text] [Related]  

  • 7. Impact of a Patient Support Program on Patient Adherence to Adalimumab and Direct Medical Costs in Crohn's Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Psoriatic Arthritis, and Ankylosing Spondylitis.
    Rubin DT; Mittal M; Davis M; Johnson S; Chao J; Skup M
    J Manag Care Spec Pharm; 2017 Aug; 23(8):859-867. PubMed ID: 28737994
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Age differences in care practices and outcomes for hospitalized patients with cancer.
    Rose JH; O'Toole EE; Dawson NV; Thomas C; Connors AF; Wenger NS; Phillips RS; Hamel MB; Cohen HJ; Lynn J
    J Am Geriatr Soc; 2000 May; 48(S1):S25-32. PubMed ID: 10809453
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of demographics, treatment patterns, health care utilization, and costs among elderly patients with extensive-stage small cell and metastatic non-small cell lung cancers.
    Karve SJ; Price GL; Davis KL; Pohl GM; Smyth EN; Bowman L
    BMC Health Serv Res; 2014 Nov; 14():555. PubMed ID: 25392276
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of Site of Death, Health Care Utilization, and Hospital Expenditures for Patients Dying With Cancer in 7 Developed Countries.
    Bekelman JE; Halpern SD; Blankart CR; Bynum JP; Cohen J; Fowler R; Kaasa S; Kwietniewski L; Melberg HO; Onwuteaka-Philipsen B; Oosterveld-Vlug M; Pring A; Schreyögg J; Ulrich CM; Verne J; Wunsch H; Emanuel EJ;
    JAMA; 2016 Jan; 315(3):272-83. PubMed ID: 26784775
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-World Characteristics and Treatment Patterns in Patients with Urticaria Initiating Omalizumab in the United States.
    Ke X; Kavati A; Wertz D; Huang Q; Wang L; Willey VJ; Stephenson JJ; Ortiz B; Paknis B; Bernstein JA; Beck LA
    J Manag Care Spec Pharm; 2018 Jul; 24(7):598-606. PubMed ID: 29952712
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factors Associated with Adherence to and Treatment Duration of Erlotinib Among Patients with Non-Small Cell Lung Cancer.
    Hess LM; Louder A; Winfree K; Zhu YE; Oton AB; Nair R
    J Manag Care Spec Pharm; 2017 Jun; 23(6):643-652. PubMed ID: 28530522
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Healthcare utilization and costs associated with COPD among SEER-Medicare beneficiaries with NSCLC.
    Shah S; Blanchette CM; Coyle JC; Kowalkowski M; Arthur ST; Howden R
    J Med Econ; 2018 Sep; 21(9):861-868. PubMed ID: 29857784
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment Patterns and Associated Health Care Costs Before and After Treatment Initiation Among Pulmonary Arterial Hypertension Patients in the United States.
    Burger CD; Ozbay AB; Lazarus HM; Riehle E; Montejano LB; Lenhart G; White RJ
    J Manag Care Spec Pharm; 2018 Aug; 24(8):834-842. PubMed ID: 29436260
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-World Treatment Patterns and Costs for Patients with Renal Cell Carcinoma Initiating Treatment with Sunitinib and Pazopanib.
    MacLean E; Mardekian J; Cisar LA; Hoang CJ; Harnett J
    J Manag Care Spec Pharm; 2016 Aug; 22(8):979-90. PubMed ID: 27459661
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An economic analysis of sublobar resection versus thermal ablation for early-stage non-small-cell lung cancer.
    Kwan SW; Mortell KE; Hippe DS; Brunner MC
    J Vasc Interv Radiol; 2014 Oct; 25(10):1558-64; quiz 1565. PubMed ID: 25130308
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness and Budgetary Consequence Analysis of Durvalumab Consolidation Therapy vs No Consolidation Therapy After Chemoradiotherapy in Stage III Non-Small Cell Lung Cancer in the Context of the US Health Care System.
    Criss SD; Mooradian MJ; Sheehan DF; Zubiri L; Lumish MA; Gainor JF; Reynolds KL; Kong CY
    JAMA Oncol; 2019 Mar; 5(3):358-365. PubMed ID: 30543349
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessing the association between medication adherence, as defined in quality measures, and disease-state control, health care utilization, and costs in a retrospective database analysis of Medicare supplemental beneficiaries using statin medications.
    Axon DR; Vaffis S; Chinthammit C; Lott BE; Taylor AM; Pickering M; Black H; Warholak T; Campbell PJ
    J Manag Care Spec Pharm; 2020 Dec; 26(12):1529-1537. PubMed ID: 33251989
    [No Abstract]   [Full Text] [Related]  

  • 19. Severe adverse events impact overall survival and costs in elderly patients with advanced non-small cell lung cancer on second-line therapy.
    Borghaei H; Yim YM; Guerin A; Pivneva I; Shi S; Gandhi M; Ionescu-Ittu R
    Lung Cancer; 2018 May; 119():112-119. PubMed ID: 29656745
    [TBL] [Abstract][Full Text] [Related]  

  • 20. End-of-life care for lung cancer patients in the United States and Ontario.
    Warren JL; Barbera L; Bremner KE; Yabroff KR; Hoch JS; Barrett MJ; Luo J; Krahn MD
    J Natl Cancer Inst; 2011 Jun; 103(11):853-62. PubMed ID: 21593012
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.